WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H527720
CAS#: 925438-34-2
Description: ACP-0052, also known as SL-052 and ACP-SL-052, is a hypocrellin-based photosensitizer potentially for the treatment of prostate cancer.
Hodoodo Cat#: H527720
Name: ACP-0052
CAS#: 925438-34-2
Chemical Formula: C35H32N2O7
Exact Mass: 592.22
Molecular Weight: 592.648
Elemental Analysis: C, 70.93; H, 5.44; N, 4.73; O, 18.90
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ACP-0052; ACP 0052; ACP0052; SL-052; SL052; SL 052; ACP-SL-052; ACP SL 052; ACPSL052
IUPAC/Chemical Name: 17-acetyl-2-hydroxy-1,5,6-trimethoxy-16-methyl-9a,10,11,12,13,13a,14,17-octahydro-3H-cyclohepta[12,1]peryleno[2,3-b]quinoxaline-3,8(9H)-dione
InChi Key: BSDCXVHKKRVTFB-UHFFFAOYSA-N
InChi Code: InChI=1S/C35H32N2O7/c1-13-10-15-23-28-24(33-32(15)36-16-8-6-7-9-17(16)37-33)18(39)11-20(42-3)26(28)27-21(43-4)12-19(40)25-30(27)29(23)31(22(13)14(2)38)35(44-5)34(25)41/h10-12,16-17,22,36-37,41H,6-9H2,1-5H3
SMILES Code: O=C(C1=C(O)C(OC)=C2C(C(C)=O)C(C)=C3)C=C(OC)C4=C1C2=C5C3=C6NC7CCCCC7NC6=C8C(C=C(OC)C4=C58)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 592.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Korbelik M, Madiyalakan R, Woo T, Haddadi A. Antitumor efficacy of photodynamic therapy using novel nanoformulations of hypocrellin photosensitizer SL052. Photochem Photobiol. 2012 Jan-Feb;88(1):188-93. doi: 10.1111/j.1751-1097.2011.01035.x. PubMed PMID: 22070614.
2: Meng Y, Zou C, Madiyalakan R, Woo T, Huang M, Yang X, Swanson E, Chen J, Xing JZ. Water-soluble and biocompatible sono/photosensitizer nanoparticles for enhanced cancer therapy. Nanomedicine (Lond). 2010 Dec;5(10):1559-69. doi: 10.2217/nnm.10.91. PubMed PMID: 21143033.
3: Xiao Z, Owen RJ, Liu W, Tulip J, Brown K, Woo T, Moore RB. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Photodiagnosis Photodyn Ther. 2010 Jun;7(2):106-14. doi: 10.1016/j.pdpdt.2010.03.003. PubMed PMID: 20510305.
